Myra Vision Announces First-in-Human Use of its Calibreye Glaucoma Drainage Device

Myra Vision announced it has initiated its first-in-human clinical study of the Calibreye System, a glaucoma drainage device with titratable outflow control designed to achieve optimal reduction of IOP for moderate to severe glaucoma patients. The prospective, non-randomized open-label feasibility study aims to evaluate the clinical procedure, safety, and overall performance of the Calibreye System in open angle glaucoma patients. 

The Calibreye System is engineered to put outflow control in the hands of glaucoma specialists, giving them the opportunity to provide personalized therapy while minimizing complications. Once implanted, the Calibreye shunt is designed to allow noninvasive in-office increases or decreases in outflow as a patient's individual treatment needs change.

"Managing glaucoma remains increasingly challenging as the condition progresses to moderate and severe stages. Unlike other glaucoma drainage devices, the titratable outflow of the Calibreye System has the potential to achieve personalized optimal IOP in our patients, with simple, in-office adjustments. I believe this is a transformative advance in the management of our patients with moderate and severe glaucoma," Rohit Varma, MD, Founding Director of Southern California Eye Institute in Los Angeles, said in a company news release.

Myra Vision and the Calibreye System will be highlighted as part of the company presentations beginning at 8:50 am CET on Thursday, September 7, 2023, during the Ophthalmology Futures European Forum in Vienna, Austria.